Skin Squamous Cell Carcinoma
13
3
5
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
7.7%
1 terminated out of 13 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (13)
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique
Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)
ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS
Oral Rigosertib for Squamous Cell Carcinoma